Identification of a CD4+ conventional T cells-related lncRNAs signature associated with hepatocellular carcinoma prognosis, therapy, and tumor microenvironment
BackgroundHepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide, and CD4+ T lymphocytes can inhibit hepatocarcinogenesis and mediate tumor regression. However, few studies have focused on the prognostic power of CD4+ Tconv-related lncRNAs in HCC patients.Method...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1111246/full |
| _version_ | 1828068569804439552 |
|---|---|
| author | Lin Zhu Lin Zhu Lin Zhu Lin Zhu Lin Zhu Xiu-Ping Zhang Xiu-Ping Zhang Xiu-Ping Zhang Xiu-Ping Zhang Shuai Xu Ming-Gen Hu Ming-Gen Hu Ming-Gen Hu Zhi-Ming Zhao Zhi-Ming Zhao Zhi-Ming Zhao Guo-Dong Zhao Guo-Dong Zhao Guo-Dong Zhao Zhao-Hui Xiao Zhao-Hui Xiao Zhao-Hui Xiao Rong Liu Rong Liu Rong Liu Rong Liu Rong Liu |
| author_facet | Lin Zhu Lin Zhu Lin Zhu Lin Zhu Lin Zhu Xiu-Ping Zhang Xiu-Ping Zhang Xiu-Ping Zhang Xiu-Ping Zhang Shuai Xu Ming-Gen Hu Ming-Gen Hu Ming-Gen Hu Zhi-Ming Zhao Zhi-Ming Zhao Zhi-Ming Zhao Guo-Dong Zhao Guo-Dong Zhao Guo-Dong Zhao Zhao-Hui Xiao Zhao-Hui Xiao Zhao-Hui Xiao Rong Liu Rong Liu Rong Liu Rong Liu Rong Liu |
| author_sort | Lin Zhu |
| collection | DOAJ |
| description | BackgroundHepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide, and CD4+ T lymphocytes can inhibit hepatocarcinogenesis and mediate tumor regression. However, few studies have focused on the prognostic power of CD4+ Tconv-related lncRNAs in HCC patients.MethodWe obtained data from TCGA and GEO databases and identified CD4+Tconv-related lncRNAs in HCC. The risk score was constructed using lasso regression and the model was validated using two validation cohorts. The RS was also assessed in different clinical subgroups, and a nomogram was established to further predict the patients’ outcomes. Furthermore, we estimated the immune cell infiltration and cancer-associated fibroblasts (CAFs) through TIMER databases and assessed the role of RS in immune checkpoint inhibitors response.ResultsWe constructed a CD4+ Tconv-related lncRNAs risk score, including six lncRNAs (AC012073.1, AL031985.3, LINC01060, MKLN1-AS, MSC-AS1, and TMCC1-AS1), and the RS had good predictive ability in validation cohorts and most clinical subgroups. The RS and the T stage were included in the nomogram with optimum prediction and the model had comparable OS prediction power compared to the AJCC. Patients in the high-risk group had a poor immune response phenotype, with high infiltrations of macrophages, CAFs, and low infiltrations of NK cells. Immunotherapy and chemotherapy response analysis indicated that low-risk group patients had good reactions to immune checkpoint inhibitors.ConclusionWe constructed and validated a novel CD4+ Tconv-related lncRNAs RS, with the potential predictive value of HCC patients’ survival and immunotherapy response. |
| first_indexed | 2024-04-11T00:06:03Z |
| format | Article |
| id | doaj.art-f3924dadcbc64201825e765533d2efe1 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T00:06:03Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-f3924dadcbc64201825e765533d2efe12023-01-09T11:42:56ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-01-011310.3389/fimmu.2022.11112461111246Identification of a CD4+ conventional T cells-related lncRNAs signature associated with hepatocellular carcinoma prognosis, therapy, and tumor microenvironmentLin Zhu0Lin Zhu1Lin Zhu2Lin Zhu3Lin Zhu4Xiu-Ping Zhang5Xiu-Ping Zhang6Xiu-Ping Zhang7Xiu-Ping Zhang8Shuai Xu9Ming-Gen Hu10Ming-Gen Hu11Ming-Gen Hu12Zhi-Ming Zhao13Zhi-Ming Zhao14Zhi-Ming Zhao15Guo-Dong Zhao16Guo-Dong Zhao17Guo-Dong Zhao18Zhao-Hui Xiao19Zhao-Hui Xiao20Zhao-Hui Xiao21Rong Liu22Rong Liu23Rong Liu24Rong Liu25Rong Liu26Medical School of Chinese PLA, Beijing, ChinaFaculty of Hepato-Biliary-Pancreatic Surgery, the First Medical Centre, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, ChinaInstitute of Hepatobiliary Surgery of Chinese PLA, Beijing, ChinaKey Laboratory of Digital Hepatobiliary Surgery, PLA, Beijing, ChinaThe First Clinical Medical School, Lanzhou University, Lanzhou, ChinaMedical School of Chinese PLA, Beijing, ChinaFaculty of Hepato-Biliary-Pancreatic Surgery, the First Medical Centre, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, ChinaInstitute of Hepatobiliary Surgery of Chinese PLA, Beijing, ChinaKey Laboratory of Digital Hepatobiliary Surgery, PLA, Beijing, ChinaDepartment of Liver Transplantation and Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, ChinaFaculty of Hepato-Biliary-Pancreatic Surgery, the First Medical Centre, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, ChinaInstitute of Hepatobiliary Surgery of Chinese PLA, Beijing, ChinaKey Laboratory of Digital Hepatobiliary Surgery, PLA, Beijing, ChinaFaculty of Hepato-Biliary-Pancreatic Surgery, the First Medical Centre, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, ChinaInstitute of Hepatobiliary Surgery of Chinese PLA, Beijing, ChinaKey Laboratory of Digital Hepatobiliary Surgery, PLA, Beijing, ChinaFaculty of Hepato-Biliary-Pancreatic Surgery, the First Medical Centre, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, ChinaInstitute of Hepatobiliary Surgery of Chinese PLA, Beijing, ChinaKey Laboratory of Digital Hepatobiliary Surgery, PLA, Beijing, ChinaFaculty of Hepato-Biliary-Pancreatic Surgery, the First Medical Centre, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, ChinaInstitute of Hepatobiliary Surgery of Chinese PLA, Beijing, ChinaKey Laboratory of Digital Hepatobiliary Surgery, PLA, Beijing, ChinaMedical School of Chinese PLA, Beijing, ChinaFaculty of Hepato-Biliary-Pancreatic Surgery, the First Medical Centre, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, ChinaInstitute of Hepatobiliary Surgery of Chinese PLA, Beijing, ChinaKey Laboratory of Digital Hepatobiliary Surgery, PLA, Beijing, ChinaThe First Clinical Medical School, Lanzhou University, Lanzhou, ChinaBackgroundHepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide, and CD4+ T lymphocytes can inhibit hepatocarcinogenesis and mediate tumor regression. However, few studies have focused on the prognostic power of CD4+ Tconv-related lncRNAs in HCC patients.MethodWe obtained data from TCGA and GEO databases and identified CD4+Tconv-related lncRNAs in HCC. The risk score was constructed using lasso regression and the model was validated using two validation cohorts. The RS was also assessed in different clinical subgroups, and a nomogram was established to further predict the patients’ outcomes. Furthermore, we estimated the immune cell infiltration and cancer-associated fibroblasts (CAFs) through TIMER databases and assessed the role of RS in immune checkpoint inhibitors response.ResultsWe constructed a CD4+ Tconv-related lncRNAs risk score, including six lncRNAs (AC012073.1, AL031985.3, LINC01060, MKLN1-AS, MSC-AS1, and TMCC1-AS1), and the RS had good predictive ability in validation cohorts and most clinical subgroups. The RS and the T stage were included in the nomogram with optimum prediction and the model had comparable OS prediction power compared to the AJCC. Patients in the high-risk group had a poor immune response phenotype, with high infiltrations of macrophages, CAFs, and low infiltrations of NK cells. Immunotherapy and chemotherapy response analysis indicated that low-risk group patients had good reactions to immune checkpoint inhibitors.ConclusionWe constructed and validated a novel CD4+ Tconv-related lncRNAs RS, with the potential predictive value of HCC patients’ survival and immunotherapy response.https://www.frontiersin.org/articles/10.3389/fimmu.2022.1111246/fullCD4+ conventional T cellslong non-coding RNAhepatocellular carcinomatumor microenvironmentprognostic signature |
| spellingShingle | Lin Zhu Lin Zhu Lin Zhu Lin Zhu Lin Zhu Xiu-Ping Zhang Xiu-Ping Zhang Xiu-Ping Zhang Xiu-Ping Zhang Shuai Xu Ming-Gen Hu Ming-Gen Hu Ming-Gen Hu Zhi-Ming Zhao Zhi-Ming Zhao Zhi-Ming Zhao Guo-Dong Zhao Guo-Dong Zhao Guo-Dong Zhao Zhao-Hui Xiao Zhao-Hui Xiao Zhao-Hui Xiao Rong Liu Rong Liu Rong Liu Rong Liu Rong Liu Identification of a CD4+ conventional T cells-related lncRNAs signature associated with hepatocellular carcinoma prognosis, therapy, and tumor microenvironment Frontiers in Immunology CD4+ conventional T cells long non-coding RNA hepatocellular carcinoma tumor microenvironment prognostic signature |
| title | Identification of a CD4+ conventional T cells-related lncRNAs signature associated with hepatocellular carcinoma prognosis, therapy, and tumor microenvironment |
| title_full | Identification of a CD4+ conventional T cells-related lncRNAs signature associated with hepatocellular carcinoma prognosis, therapy, and tumor microenvironment |
| title_fullStr | Identification of a CD4+ conventional T cells-related lncRNAs signature associated with hepatocellular carcinoma prognosis, therapy, and tumor microenvironment |
| title_full_unstemmed | Identification of a CD4+ conventional T cells-related lncRNAs signature associated with hepatocellular carcinoma prognosis, therapy, and tumor microenvironment |
| title_short | Identification of a CD4+ conventional T cells-related lncRNAs signature associated with hepatocellular carcinoma prognosis, therapy, and tumor microenvironment |
| title_sort | identification of a cd4 conventional t cells related lncrnas signature associated with hepatocellular carcinoma prognosis therapy and tumor microenvironment |
| topic | CD4+ conventional T cells long non-coding RNA hepatocellular carcinoma tumor microenvironment prognostic signature |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1111246/full |
| work_keys_str_mv | AT linzhu identificationofacd4conventionaltcellsrelatedlncrnassignatureassociatedwithhepatocellularcarcinomaprognosistherapyandtumormicroenvironment AT linzhu identificationofacd4conventionaltcellsrelatedlncrnassignatureassociatedwithhepatocellularcarcinomaprognosistherapyandtumormicroenvironment AT linzhu identificationofacd4conventionaltcellsrelatedlncrnassignatureassociatedwithhepatocellularcarcinomaprognosistherapyandtumormicroenvironment AT linzhu identificationofacd4conventionaltcellsrelatedlncrnassignatureassociatedwithhepatocellularcarcinomaprognosistherapyandtumormicroenvironment AT linzhu identificationofacd4conventionaltcellsrelatedlncrnassignatureassociatedwithhepatocellularcarcinomaprognosistherapyandtumormicroenvironment AT xiupingzhang identificationofacd4conventionaltcellsrelatedlncrnassignatureassociatedwithhepatocellularcarcinomaprognosistherapyandtumormicroenvironment AT xiupingzhang identificationofacd4conventionaltcellsrelatedlncrnassignatureassociatedwithhepatocellularcarcinomaprognosistherapyandtumormicroenvironment AT xiupingzhang identificationofacd4conventionaltcellsrelatedlncrnassignatureassociatedwithhepatocellularcarcinomaprognosistherapyandtumormicroenvironment AT xiupingzhang identificationofacd4conventionaltcellsrelatedlncrnassignatureassociatedwithhepatocellularcarcinomaprognosistherapyandtumormicroenvironment AT shuaixu identificationofacd4conventionaltcellsrelatedlncrnassignatureassociatedwithhepatocellularcarcinomaprognosistherapyandtumormicroenvironment AT minggenhu identificationofacd4conventionaltcellsrelatedlncrnassignatureassociatedwithhepatocellularcarcinomaprognosistherapyandtumormicroenvironment AT minggenhu identificationofacd4conventionaltcellsrelatedlncrnassignatureassociatedwithhepatocellularcarcinomaprognosistherapyandtumormicroenvironment AT minggenhu identificationofacd4conventionaltcellsrelatedlncrnassignatureassociatedwithhepatocellularcarcinomaprognosistherapyandtumormicroenvironment AT zhimingzhao identificationofacd4conventionaltcellsrelatedlncrnassignatureassociatedwithhepatocellularcarcinomaprognosistherapyandtumormicroenvironment AT zhimingzhao identificationofacd4conventionaltcellsrelatedlncrnassignatureassociatedwithhepatocellularcarcinomaprognosistherapyandtumormicroenvironment AT zhimingzhao identificationofacd4conventionaltcellsrelatedlncrnassignatureassociatedwithhepatocellularcarcinomaprognosistherapyandtumormicroenvironment AT guodongzhao identificationofacd4conventionaltcellsrelatedlncrnassignatureassociatedwithhepatocellularcarcinomaprognosistherapyandtumormicroenvironment AT guodongzhao identificationofacd4conventionaltcellsrelatedlncrnassignatureassociatedwithhepatocellularcarcinomaprognosistherapyandtumormicroenvironment AT guodongzhao identificationofacd4conventionaltcellsrelatedlncrnassignatureassociatedwithhepatocellularcarcinomaprognosistherapyandtumormicroenvironment AT zhaohuixiao identificationofacd4conventionaltcellsrelatedlncrnassignatureassociatedwithhepatocellularcarcinomaprognosistherapyandtumormicroenvironment AT zhaohuixiao identificationofacd4conventionaltcellsrelatedlncrnassignatureassociatedwithhepatocellularcarcinomaprognosistherapyandtumormicroenvironment AT zhaohuixiao identificationofacd4conventionaltcellsrelatedlncrnassignatureassociatedwithhepatocellularcarcinomaprognosistherapyandtumormicroenvironment AT rongliu identificationofacd4conventionaltcellsrelatedlncrnassignatureassociatedwithhepatocellularcarcinomaprognosistherapyandtumormicroenvironment AT rongliu identificationofacd4conventionaltcellsrelatedlncrnassignatureassociatedwithhepatocellularcarcinomaprognosistherapyandtumormicroenvironment AT rongliu identificationofacd4conventionaltcellsrelatedlncrnassignatureassociatedwithhepatocellularcarcinomaprognosistherapyandtumormicroenvironment AT rongliu identificationofacd4conventionaltcellsrelatedlncrnassignatureassociatedwithhepatocellularcarcinomaprognosistherapyandtumormicroenvironment AT rongliu identificationofacd4conventionaltcellsrelatedlncrnassignatureassociatedwithhepatocellularcarcinomaprognosistherapyandtumormicroenvironment |